<DOC>
	<DOCNO>NCT01596816</DOCNO>
	<brief_summary>The aim study assess safety hypofractionated stereotactic boost radiation ( prostate ) normofractionated radiotherapy ( prostate + seminal vesicle ) .</brief_summary>
	<brief_title>Hypofractionated Stereotactic Boost Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Prostate adenocarcinoma prove histology With least one intermediaterisk criterias : T2b and/or PSA 10 et 20 ng/ml and/or Gleason score = 7 Prostatic volume â‰¤ 80 cc No adenopathy ( lymph node &lt; 1.5 cm scanner MRI and/or lymph node dissection ) No metastasis ( bone scan ) Age &gt; = 18 an No prior pelvic irradiation No prior anticancer treatment ( prostatectomy , chemotherapy , hormonotherapy &gt; 3 month ) Performance status ( ECOG ) &lt; 1 No contraindication fiducials implantation , hemostasis disorder must treat implantation Life expectancy &gt; = 10 week Patient affiliate health insurance Informed consent sign patient Cancer histologically prove Unfavorablerisk ( T2c and/or PSA &gt; 20 ng/ml and/or Gleason &gt; 7 ) Favorablerisk ( T1c T2a PSA &lt; 10 ng/ml Gleason &lt; 7 ) T3 T4 History cancer uncontrolled and/or treat since less 5 year ( except basal cell carcinoma skin ) Contraindication MRI IPSS score &gt; 10 Recurrent metastatic disease Allergy gold Patient already include another therapeutic trial experimental molecule Unable medical followup ( geographic , social mental reason )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>